he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
提示信源地址
- 2022-05-022013年国际抗癫痫执行委员会抗癫痫药使用指南
- 2022-04-26吡仑帕奈辅助用药可改善部分发作型高血压患者的症状
- 2022-04-13抗癫痫药物预防新发癫痫:任重而道远
- 2022-04-11诺华银屑病药物 Secukinumab 比依那西普好
- 2022-04-11奥硝唑、甲硝唑和替硝唑有什么区别?
- 2022-04-07你知道吗?快看护理知识!
- 抗癫痫药物预防新发癫痫:任重而道远
- 婴儿身上的白斑是白癜风吗?
- 诺华银屑病药物 Secukinumab 比依那西普好
- 奥硝唑、甲硝唑和替硝唑有什么区别?
- 你知道吗?快看护理知识!
- 预测癫痫患者再入院风险
- 什么是霉菌性阴炎?
- 银屑病常用药物进入医疗保险,有效减轻患者的医疗负担
- 福州一医院用嫩模照片宣传妇科被判赔偿3.2 万
- 常见妇科炎症的相关问答
- 白癜风的病因是什么?
- 生发偏方 4种生发偏方使头发更浓密
- 不注意这些问题,吃多少药都没用!
- 治疗白癜风的方法很多
- Neurology:颅脑损伤增加了迟发性癫痫的风险,高损伤频率、重伤、老年人尤其是
- 癫痫患者停药问题解决了吗?最新的预测模型已经发布!
- 男性胀痛三年,羞于就医 专家:男性也有乳腺疾病
- 女生有妇科炎症,能自愈吗?
- 特发性癫痫大发作药物治疗的首选
- 煮螃蟹的方法 这样吃螃蟹味道也不错
- Cell重磅:解决了近百年的问题!研究发现了闪过记忆的潜在机制
- 继发性癫痫能治愈吗 治疗癫痫有几个步骤
- 答疑┃什么样的月经是健康正常的?这几项你达标了吗?
- Alz Res Therapy:健康饮食可以降低痴呆的风险
- Circ Ep:左室肥厚高血压患者新发房颤增加SCD风险
- 【用药问答】癫痫发作和局限性发作的首选治疗是什么?
- 叶能治疗白癜风吗?
- 高血压病小发作症状 这些症状就是高血压小发作
- 老年人得了癫痫病有什么患者
- 物理疗法能治高血压吗
- 女性癫痫病怎么治疗更快
- 戴只手表就能测中风?智能穿戴设备太牛了
- 一种特异性的癫痫中风类型【视频】
- 引起癫痫病的病因有什么
- 《柳叶刀》点名:中国饮食有3大健康杀手,血管病和白血病世界第一
- 2015 神经系统癌症诊疗进展大盘点
- 成年人癫痫有哪些病征
- 癫痫病症状 怎样医护癫痫病人
- 如何诊断中学生癫痫病
- 抑郁症的危害 抑郁症不治会引起死亡吗